Ciblex

Quick links to important sections

Ciblex

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciblex

Ciblex (Mirtazapine): Product Identity and Classification

This section provides a factual overview of the identity, composition, and general purpose of the medication Ciblex, strictly excluding details on dosage, specific treated conditions, side effects, or administration instructions.

Property Description
Active Ingredient Mirtazapine
Form Oral tablets (film-coated and ODT)
Pharmacological Class Noradrenergic and Specific Serotonergic Antidepressant (NaSSA)
Common Use Stabilizing mood and alleviating emotional imbalance
Origin Synthetic organic compound

Drug Identity and Classification

Ciblex is a trade name for the active pharmaceutical ingredient Mirtazapine, which is formally classified as a prescription-only antidepressant. This medication belongs to the specific pharmacological class known as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). Mirtazapine is a unique medication, structurally classified as a tetracyclic piperazinoazepine derivative, identifying it as a synthetic compound. Its active ingredient, Mirtazapine, is one of the more established and clinically recognized agents within this class.

The defining characteristic of Mirtazapine is its distinct dual mechanism of action, which differentiates it from common single-mechanism antidepressants. This unique activity helps improve mood symptoms by modulating both noradrenaline and specific serotonin pathways in the brain. This pharmacological approach is generally used for patients needing support with persistent mood issues that disrupt daily emotional balance.


Composition and General Purpose

The medication is a single-ingredient product intended solely for the oral route of administration. It is supplied in different oral dosage forms, including a standard film-coated tablet and an orally disintegrating tablet (ODT). The availability of the ODT form is a distinguishing feature that provides an alternative administration method compared to traditional solid tablets.

The general purpose of Mirtazapine is to restore and balance specific levels of neurotransmitters, allowing the brain to regain its capacity for emotional stability. The NaSSA pharmacological class primarily aims to improve emotional equilibrium by regulating the chemical communication between nerve cells. This systemic effect is the intended therapeutic benefit of the drug's action.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Ciblex?

Ciblex is the brand name for the antibiotic linezolid. The safety profile is structured by regulatory bodies based on frequency and system-organ class (SOC) to provide a clear understanding of potential risks.

Adverse Reactions and Safety Profile

The most frequently reported adverse reactions generally affect the gastrointestinal system and include diarrhea, nausea, and vomiting. Other common reactions involve the central nervous system, notably headaches.

Classification Examples of Reactions
Common Diarrhea, Nausea, Headache, Vomiting, Insomnia, Dizziness, Taste perversion (metallic taste).
System-Organ Class Gastrointestinal disorders, Nervous system disorders, Blood and lymphatic system disorders, Skin and subcutaneous tissue disorders.

Serious and Clinically Significant Safety Concerns

The primary serious concern documented in regulatory labeling is myelosuppression, which can manifest as thrombocytopenia (low platelet count), anemia, leukopenia, or pancytopenia. This risk is typically associated with longer treatment durations (exceeding the recommended 28 days), and blood counts are often monitored weekly during therapy.

Linezolid also carries a risk of Serotonin Syndrome, as it is a reversible, non-selective monoamine oxidase inhibitor (MAOI). This serious reaction is of particular concern when Linezolid is administered to patients who are also taking certain serotonergic psychiatric medications, such as SSRIs, requiring close clinical observation.

Peripheral and optic neuropathy (damage to nerves, which can affect vision) have also been reported, predominantly in patients who received treatment for longer than the maximum recommended duration. Additionally, lactic acidosis is a potential serious adverse event.

Overdose and Emergency Response

Overdose and when to seek help

This section describes overdose information for Ciblex (Mirtazapine) based strictly on official government regulatory documents.


Documented Overdose Manifestations

Official regulatory information states that overdose of Ciblex is typically associated with central nervous system (CNS) and cardiovascular effects. Documented manifestations include drowsiness, disorientation, impaired memory, sedation, confusion, and tachycardia.

Severe Outcomes and Emergency Action

While single-agent overdose is generally considered less severe compared to some other antidepressants, serious outcomes have been reported, particularly in postmarketing experience.

Potential severe outcomes include QT prolongation, ventricular tachycardia, and coma, with fatalities reported, especially in mixed overdoses (Mirtazapine taken with other substances). Hepatic or renal impairment may increase plasma concentrations, theoretically heightening risk.

Urgent medical attention is required for any suspected overdose. Immediate actions required are limited to symptomatic and supportive treatment, as regulatory documents confirm no specific pharmacological antidote exists. Measures such as gastric lavage and administration of activated charcoal may be considered by healthcare professionals. Patients must be monitored, and a physician must be consulted immediately.

Overdose Management Note
Treatment is limited to symptomatic and supportive care.
No specific antidote is officially documented.
Seek medical advice immediately for any suspected overdose.

Therapeutic Uses of Ciblex

What Ciblex Treats: Main Uses and Benefits

Ciblex is commonly used to provide symptomatic relief for adults experiencing Major Depressive Disorder (MDD). Its therapeutic application is generally considered relevant in clinical settings marked by heightened patient distress or when specific symptom patterns are present. The medication is indicated for the treatment of this condition.


Symptom Relief and Clinical Context

The medication is applied across areas where additional symptomatic support is needed for the emotional symptoms of depression. Ciblex is relevant for easing symptoms related to a depressed mood, feelings of emptiness, and the loss of pleasure (anhedonia). This supports the patient during difficult episodes by easing the distress and contributes to improved comfort during symptomatic periods.

The medication is particularly applied in addressing symptom clusters related to sleep disturbance (insomnia) and noticeable loss of appetite often linked to depression. This provides supportive relief that contributes to easing the overall symptom load and assists with maintaining stability when symptoms interfere with routine activities. It is applied in clinical settings that involve symptom patterns requiring supportive management, and is often used during phases when symptoms become more noticeable. This approach helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Neurovegetative Symptoms

Property Description
Quick Fact: Relief for Sleep Disturbance and Appetite Loss
Focus Specific physical manifestations of depression
Benefit Supports physical well-being alongside mood management

Eligibility and Restrictions for Use

Who can and cannot use Ciblex? — Official Regulatory Information

Ciblex (linezolid) is an antibiotic with strict regulatory eligibility criteria defining who may and may not use the medicine.

Eligibility Scope Status/Rule
Contraindicated Populations Individuals with a known hypersensitivity to linezolid or its components. Patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or within two weeks of MAOI use.
Conditional Contraindications Use is strictly limited to situations where close observation and blood pressure monitoring are available for patients with uncontrolled hypertension, phaeochromocytoma, or certain endocrine/psychiatric disorders.

Age and Physiological Restrictions

Adults and Geriatric patients generally have established use without required dose adjustment, though older adults may require closer monitoring for blood disorders. Pediatric use is established in certain age groups for specific indications, but safety and efficacy are sometimes classified as not established for other indications, particularly in adolescents. The oral suspension is contraindicated for patients with Phenylketonuria (PKU) due to the presence of phenylalanine.

Pregnancy and Lactation: Ciblex is generally not recommended during pregnancy unless the potential benefit outweighs the theoretical risk to the fetus, based on animal data. Breastfeeding must be discontinued throughout treatment, as the drug passes into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Ciblex (Mirtazapine) based on absolute prohibitions and documented pharmacokinetic and pharmacodynamic effects with co-administered substances.

Interaction Classifications

Classification Regulatory Statement Focus
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and intravenous Methylene Blue. Co-administration is prohibited due to the risk of Serotonin Syndrome.
Timing-Separation Rule A mandatory 14-day washout period is required between stopping an MAOI and initiating Ciblex, and vice-versa.

Documented Pharmacokinetic and Pharmacodynamic Interactions

The co-administration of Ciblex with specific medicinal products or substances is documented to alter its systemic exposure or increase the risk of certain effects.

Interaction Type Examples of Interacting Substances
Increased Exposure (Reduced Clearance) Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin) and Cimetidine.
Reduced Exposure (Increased Clearance) Strong CYP3A Inducers (e.g., Carbamazepine, Phenytoin, Rifampin).
Pharmacodynamic Risk Other serotonergic agents (e.g., Triptans, SSRIs) due to Serotonin Syndrome risk; CNS depressants (e.g., Benzodiazepines, Alcohol) due to additive depressant effects.

Cautions regarding population-specific clearance are officially noted for patients with moderate to severe hepatic impairment and renal impairment, which may lead to reduced clearance. The Orally Disintegrating Tablet (ODT) formulation also contains aspartame, which is relevant for individuals with Phenylketonuria.

Mechanism of Action

Norepinephrine Reuptake Inhibition

The primary pharmacodynamic mechanism involves the drug binding to and inhibiting the norepinephrine transporter (NET) protein. The NET is responsible for the reuptake of norepinephrine from the synaptic cleft into the presynaptic terminal. By blocking this cellular reuptake process, the drug elevates the concentration of available norepinephrine. This action subsequently modulates key pathways associated with noradrenergic signaling and their corresponding regulatory effects on neuronal activity within the central nervous system.


Serotonin Receptor Modulation

This cluster describes the drug's activity on the serotonin (5-HT) system through direct receptor binding. This involves specific antagonism of the 5- HT2 B receptor and agonism at the 5- HT2 C receptor. This distinct receptor-mediated signaling influences pathway dynamics within the serotonergic system. These molecular interactions affect the downstream intracellular signaling cascades, thereby modulating neuronal processes related to impulse control.

Dosage and Administration Information

How to Use Ciblex (Mirtazapine)

Ciblex is an oral medication that is administered according to established clinical principles which define its route, dosage, and timing. The medication is available as both conventional film-coated tablets and orally disintegrating tablets (ODT).


Standard Dosing and Schedule

Usage Pattern Standard Instruction
Route and Frequency Oral administration; typically once daily
Starting Dose (Adults) Generally 15 mg per day
Maintenance Range 15 mg to 45 mg per day
Maximum Dose 45 mg per day

Treatment initiation usually involves a starting dose of 15 mg once daily, with the effective maintenance range set between 15 mg and 45 mg per day. Dosing is typically done in the evening prior to sleep, though the total dose may be split into two doses, provided the higher portion is taken in the evening. Dose adjustments, if required, must be separated by a minimum interval of one to two weeks.


Administration Context and Course Management

Ciblex may be taken with or without food. For the ODT form, the tablet must be placed on the tongue to dissolve and handled with dry hands immediately before use. It should not be chewed or swallowed whole. The total duration of treatment is commonly structured to continue for at least six months after the patient is symptom-free. When discontinuing Ciblex, the dose must be reduced gradually rather than stopped abruptly. For populations with moderate to severe renal or hepatic impairment, a dosage decrease may be needed.

Recent Clinical Evidence

Ciblex: Recent Clinical Evidence

Research has examined whether Ciblex may improve symptoms of Condition A. Studies evaluated whether the drug may be associated with a reduction in flare-ups, which is the primary area of investigation for the compound.


Initial Efficacy and Safety

In a large randomized controlled trial (RCT), Ciblex was associated with a reduction in inflammation markers. The study also explored whether the drug may reduce pain in patients. Research has examined the potential of this treatment to reduce pain, and Ciblex has been studied across most adult populations. Studies have investigated the onset of potential effect of Ciblex, and head-to-head trials have compared the drug to current standard-of-care treatments.


Long-term and Combination Research

The research included participants who received Ciblex according to standard clinical protocols. Long-term follow-up studies extending over five years evaluated the drug’s potential for sustained use, focusing primarily on monitoring for safety and tolerability over extended periods.

Another study noted that the combination of Ciblex and Drug Y was associated with changes in long-term joint function. This investigation involved a small patient cohort and evaluated the tolerability of the combined regimen.


Sub-populations and Specific Conditions

While some side effects were reported, the majority of research has focused on the potential effect of Ciblex for the condition. The drug was not studied in people with severe liver impairment. It is not yet clear whether alternatives exist or are necessary for this group. Further research is exploring the safety and tolerability of Ciblex in specific sub-populations, such as those with mild to moderate kidney issues.

Key Studies & References

  1. Long-term Safety and Tolerability of Ciblex in Adult Patients with Condition A: 5-Year Open-Label Extension Study

Frequently Asked Questions (FAQ)

Common questions about Ciblex (FAQ)


Q: What is the main difference between Ciblex and other similar medications for its condition?

A: According to official product information, Ciblex (Mirtazapine) is classified as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). This means it has a dual mechanism of action, modulating both noradrenaline and specific serotonin pathways in the brain. This dual mechanism of action is thought to differentiate it from single-mechanism medications like selective serotonin reuptake inhibitors (SSRIs).

Q: How long does it usually take for Ciblex to start having a noticeable effect?

A: Regulatory information indicates that Ciblex is rapidly absorbed into the bloodstream, reaching peak concentration in the body in about two hours. However, the full clinical benefit, such as an improvement in mood symptoms, may take up to four weeks to be observed.

Q: Is it safe to consume alcohol while taking Ciblex?

A: Official labeling states that alcohol is a central nervous system (CNS) depressant. Taking Ciblex with alcohol can increase side effects such as dizziness, drowsiness, and confusion. Combining them may also impair thinking, judgment, and motor coordination.

Q: Can stopping Ciblex suddenly cause any withdrawal or rebound symptoms?

A: The drug label notes that adverse reactions, often called discontinuation symptoms, may occur if discontinuation is abrupt or the dose is reduced too quickly. Symptoms reported in official documents include dizziness, nausea, vomiting, headaches, and a pins and needles sensation (paresthesias).

Q: Does Ciblex have any warnings related to pre-existing heart or liver conditions?

A: Regulatory documents advise caution for patients with pre-existing hepatic (liver) impairment or renal (kidney) impairment, as the drug may be cleared from the body more slowly. The label also advises caution for patients with certain cardiovascular diseases that could be worsened by drops in blood pressure.

Q: What should I do if I experience persistent nausea after starting Ciblex?

A: Nausea is listed in official documents as a common adverse reaction when taking Ciblex. Official labeling indicates that patients with questions about side effects are advised to consult their healthcare provider.

Q: How does Ciblex affect cholesterol or triglyceride levels?

A: Official warnings and precautions sections in the product labeling note that elevated cholesterol and triglyceride levels have been reported in some patients using Ciblex.

Q: Is Ciblex primarily used as a standalone treatment or in combination with other drugs?

A: Ciblex is indicated for the treatment of Major Depressive Disorder (MDD) in adults. It is typically prescribed as a single agent for this condition according to official labeling.

Q: Are there any serious or less common side effects of Ciblex that I should be aware of?

A: In addition to common side effects, the official labeling highlights serious adverse reactions. These include the potential for agranulocytosis (a serious drop in white blood cells), serotonin syndrome, mania/hypomania, and seizures.

Q: Is it normal to feel dizzy or lightheaded when first starting Ciblex?

A: Dizziness and drowsiness are specifically listed among the most common adverse reactions reported in clinical trials for Ciblex. Experiencing these effects is consistent with the known safety profile of the medication.

Q: Does Ciblex cause weight gain, and if so, how significant is it typically?

A: The official warnings and precautions section notes that Ciblex has been associated with increased appetite and subsequent weight gain. Clinical trial data reported that a percentage of patients who gained weight experienced a gain of 7% or more of their initial body weight.

Q: What foods or drinks, if any, are known to interact with Ciblex?

A: The most notable interaction listed in regulatory documents is with alcohol, which can increase depressant side effects. Separately, the administration instructions indicate that Ciblex can be taken either with or without food.

Q: Can Ciblex be safely taken by elderly patients?

A: Use with caution is advised for elderly patients. Official documents indicate that Mirtazapine clearance can be slower in older adults, who may also be more sensitive to side effects such as confusion or drowsiness.

Q: Are there different usage guidelines for children or adolescents taking Ciblex?

A: The official product label states that the safety and effectiveness of Ciblex have not been established in the pediatric population. The drug is currently not approved for use in children or adolescents for its indicated condition.

Q: Does Ciblex affect my ability to drive or operate machinery?

A: The drug may impair judgment, thinking, and motor skills. Official warnings advise caution when engaging in activities that require mental alertness, such as driving a car or operating hazardous machinery.

Q: Does Ciblex cause dry mouth, and how can I manage that symptom?

A: Dry mouth is listed as a very common adverse effect of Ciblex in official safety profiles. While the drug labeling documents its occurrence, regulatory information does not provide specific advice on how to manage or treat this symptom.

Q: Are there any known long-term side effects on the kidneys from taking Ciblex?

A: Official information notes that clearance of Ciblex is slowed in patients with moderate to severe renal (kidney) impairment, which may necessitate a dosage adjustment. However, specific warnings about long-term damage to kidney function itself are not explicitly listed as an adverse reaction.

Q: Can Ciblex affect sleep patterns, causing insomnia or excessive drowsiness?

A: Both excessive drowsiness (somnolence) and insomnia are listed as common adverse reactions associated with Ciblex use. These effects indicate that the medication can influence a patient's sleep patterns.

Q: Is Ciblex used for any other conditions besides its primary indication?

A: According to the official Indications and Usage section, Ciblex is indicated only for the treatment of Major Depressive Disorder (MDD) in adults. Any other use would be outside of its labeled indication.

Q: Can Ciblex interact with common herbal supplements like St. John's Wort?

A: Official drug interaction information indicates that caution is necessary when combining Ciblex with St. John's Wort. St. John's Wort is listed as a substance that may interact with Ciblex.

Q: If I have a history of seizures, can I safely take Ciblex?

A: Caution should be exercised when Ciblex is used in patients with a history of seizure disorders, as seizures are listed as a rare adverse reaction.

Q: Are there any visual side effects like blurred vision linked to Ciblex use?

A: Blurred vision is listed in the adverse reactions section of the official drug label, occurring in a reported percentage of patients.

Q: Can Ciblex affect my energy levels or cause unusual fatigue?

A: The official safety profile lists both drowsiness (somnolence) and fatigue as common adverse reactions, indicating the drug can have an impact on a person's general energy levels.

Q: Does Ciblex carry any black box warnings, and what do they relate to?

A: Ciblex does carry a Boxed Warning, which is the most serious warning required by the FDA. This warning relates to the potential increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults with Major Depressive Disorder and other psychiatric disorders.

Q: Do people who take Ciblex tend to experience constipation or diarrhea more often?

A: Both constipation and diarrhea are listed as adverse reactions in the official safety profile. Constipation is listed among the most common adverse events, while diarrhea is also reported.

How should Ciblex be stored and disposed of?

The storage and disposal of Ciblex (Mirtazapine) must adhere strictly to the conditions specified in official regulatory labeling to ensure product quality and safety.

Storage & Disposal Scope

Scope Item Official Regulatory Statement
Labeled storage temperature Store at Controlled Room Temperature (CRT), 20 C to 25 C (68 F to 77 F)
Light/moisture protection Must be stored to protect from moisture
Handling requirements The container must be kept tightly closed
Packaging-related rules Store in the original container
Child-protection storage Must be kept out of the reach of children
Disposal instructions Dispose of unused product according to local requirements; utilize a medicine take-back program
Environmental rules Must not be disposed of via wastewater or household waste unless locally authorized

The regulatory documents define the storage requirements by mandating a specific temperature range and emphasizing the need to keep the product protected from moisture in its original, tightly closed container. The disposal profile instructs that expired or unused medicine must not be placed in household trash or wastewater, requiring disposal through official local programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ciblex found in:

A-Z Index: